Divi's Labs - Custom Synthesis Drive Numbers; Generics Muted: ICICI Direct
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
ICICI Direct Report
Divi’s Laboratories Ltd. is engaged in manufacturing generic active pharma ingredients and intermediates, custom synthesis of active ingredients and advanced intermediates for pharma mulit-national companies, other speciality chemicals like Carotenoids and complex compounds like peptides and Nucleotide revenues.
Key triggers for future price performance:
Divi's Labs has been building capacities in a few more niche APIs as per the evolving demand scenario in the backdrop of ‘China plus one’ opportunities.
progress towards six identified growth areas- 1. established generics, 2. existing generics, 3. new generics, 4. Sartan APIs, 5. contrast media, 6. custom synthesis.
traction from some near term Covid-19 opportunities such as Molnupiravir API (MSD’s) authorised manufacturer.
progress on the Kakinada greenfield project (planned outlay Rs 1000-2000 crore).
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.